Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-01

Clinical Trial Update: Lasmiditan Compared to Placebo in the Acute Treatment of Migraine in Korean [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lasmiditan to placebo for acute treatment of migraine in Korean population has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lasmiditan (Lasmiditan)

Snippet

Sponsor: IlDong Pharmaceutical Co Ltd | Conditions: Acute Migraine | Phase 3 | Status: COMPLETED